Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
GLT-1 Upregulation Mitigates TBI via CB1-CREB Pathway Inhibi
2026-06-11
This study demonstrates that increasing GLT-1 expression in astrocytes reduces neuronal apoptosis and cognitive dysfunction after traumatic brain injury (TBI) in mice, mechanistically implicating the CB1-CREB signaling pathway. The findings provide new insight into glutamate homeostasis regulation and position CB1 receptor antagonism as a promising target in TBI research.
Pemetrexed in Translational Oncology: Mechanism to Precision
2026-06-10
This article provides translational researchers with a mechanistic roadmap for integrating pemetrexed—a multitargeted antifolate antimetabolite—into advanced cancer chemotherapy research. By dissecting the molecular rationale behind pemetrexed’s inhibition of key enzymes in nucleotide biosynthesis and connecting these insights to gene expression profiling and DNA repair vulnerabilities, we illuminate strategic paths for overcoming chemoresistance in tumor models such as non-small cell lung carcinoma and malignant mesothelioma. Building on recent evidence and comparative literature, we guide protocol design and combination strategies, positioning APExBIO’s pemetrexed as a pivotal tool for next-generation functional genomics and therapeutic innovation.
Zosuquidar (LY335979) 3HCl: Precision P-gp Inhibition for MD
2026-06-10
Discover how Zosuquidar (LY335979) 3HCl enables targeted, reproducible reversal of multidrug resistance (MDR) in cancer by selectively inhibiting P-glycoprotein. This article uniquely explores pharmacokinetic nuances and tissue-specific applications, providing advanced assay guidance for oncology research.
BicD and MAP7 Synergize to Activate Drosophila Kinesin-1
2026-06-09
This study elucidates how the adaptor protein BicD and microtubule-associated protein MAP7 work together to activate homodimeric Drosophila kinesin-1 by relieving auto-inhibition and enhancing microtubule engagement. The findings clarify distinct, complementary mechanisms of motor activation and have broad implications for understanding intracellular transport regulation.
In Vitro Activity of Midecamycin Against Diverse Bacterial I
2026-06-09
This study systematically evaluated the in vitro antibacterial activity of midecamycin, a new acetoxy-substituted macrolide, against a range of gram-positive and gram-negative clinical isolates. The findings highlight midecamycin’s spectrum, its limitations regarding erythromycin-resistant strains, and offer comparative insights with established antibiotics like vancomycin, informing the rational selection of antibacterial agents for resistance studies.
Phosphatase Inhibitor Cocktail: Maximizing Protein Phosphory
2026-06-08
The Phosphatase Inhibitor Cocktail (2 Tubes, 100X) from APExBIO delivers broad-spectrum serine/threonine and tyrosine phosphatase inhibition to preserve labile phosphorylation states during sample preparation. Its dual-tube design, validated in advanced cancer research and proteomics, streamlines workflows for reproducible immunoblotting and kinase assays.
Mast Cells Drive Breast Cancer Progression via IFN-β Pathway
2026-06-08
This study elucidates how tumor-resident mast cells accelerate breast cancer progression by activating the type I interferon pathway through IFN-β signaling. The findings reveal a bidirectional crosstalk that sustains cancer stemness, offering mechanistic insight and highlighting potential therapeutic targets for disrupting the tumor immune microenvironment.
Zosuquidar (LY335979) 3HCl: P-gp Inhibition for MDR Reversal
2026-06-07
Zosuquidar (LY335979) 3HCl is a potent, selective P-glycoprotein inhibitor that reverses multidrug resistance in cancer models. At low micromolar doses, it restores sensitivity to chemotherapeutics without altering pharmacokinetics. The compound is well-characterized for research workflows targeting P-gp-mediated resistance.
Early Pheromone Perception Alters Neurodegeneration in C. el
2026-06-06
Peng et al. (2023) demonstrate that pheromone exposure during early development in C. elegans irreversibly remodels neurodevelopment and accelerates adult neurodegeneration via insulin signaling and autophagy inhibition. This study provides mechanistic insight into how environmental chemical cues can modulate neuronal health and disease progression.
Topotecan in Cancer Therapy: Mechanisms and Clinical Insight
2026-06-05
The reference review details the pharmacology and clinical use of topotecan, a topoisomerase I inhibitor, highlighting its unique mechanism of action and efficacy in treating small cell lung and ovarian cancers. The findings inform combination chemotherapy strategies and provide comparative context for the established DNA crosslinking agent cisplatin.
Balancing Self-Renewal and Differentiation in Human Intestin
2026-06-05
This study introduces a tunable organoid culture system that achieves a controlled equilibrium between stem cell self-renewal and differentiation, addressing a longstanding limitation in human intestinal organoid models. By leveraging small molecule pathway modulators, the system enhances both cellular diversity and proliferative capacity, making it suitable for high-throughput and disease modeling applications.
Phosphatase Inhibitor Cocktail 1: Preserving Protein Phospho
2026-06-04
Phosphatase Inhibitor Cocktail 1 (100X in DMSO) is a broad-spectrum alkaline phosphatase inhibitor designed to preserve protein phosphorylation during sample preparation. Its use is critical for accurate phosphoproteomic analysis and reliable protein signaling studies. This article summarizes its mechanism, evidence base, optimal use parameters, and key limitations.
Co-Targeting BRD4 and RAC1 Disrupts Epigenetic Drivers in Br
2026-06-04
This study reveals that simultaneous inhibition of BRD4 and RAC1 destabilizes key oncogenic networks in multiple breast cancer subtypes by disrupting the c-MYC-G9a-FTH1 axis and downregulating HDAC1. The findings provide mechanistic insight into epigenetic vulnerabilities and offer a preclinical framework for combinatorial therapies targeting tumor growth, stemness, and metastasis.
Ultrafiltration Enables High-Purity Circular RNA Isolation
2026-06-03
Guillen-Cuevas et al. introduce ultrafiltration as a scalable and effective method for purifying circular RNA (circRNA) from mixtures produced by in vitro transcription and self-splicing. Their work achieves much higher purity and yield than conventional methods, providing a foundation for future circRNA-based therapeutic manufacturing.
Lisinopril Dihydrate: Precision ACE Inhibitor for Translatio
2026-06-03
Lisinopril dihydrate, a potent long-acting ACE inhibitor, empowers researchers with unmatched selectivity and reproducibility in hypertension, heart failure, and diabetic nephropathy models. Discover optimized protocols, advanced applications, and troubleshooting strategies that set APExBIO’s offering apart for rigorous cardiovascular and renal research.
8150 records 19/544 page Previous Next First page 上5页 1617181920 下5页 Last page